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High serum levels of soluble CD44 variant isoform v5
are associated with favourable clinical outcome in
ovarian cancer
AG Zeimet, M Widschwendter, M Uhl-Steidi, E Muller-Holzner, G Daxenbichier, C Marth and 0 Dapunt
Department of Obstetrics and Gynecology, University Hospital, Innsbruck, Austria
Summary In 96 ovarian cancer patients, the present study investigates the clinical significance of pretreatment concentrations of soluble
CD44 standard (CD44s) and its isoforms v5 and v6 determined in the serum and the ascitic fluid by means of recently developed enzyme-
linked immunosorbent assays (ELISAs). Furthermore, CD44 serum concentrations in the ovarian cancer patients were compared with
circulating CD44 levels in 50 healthy age-matched female blood donors. Whereas CD44s was found to be higher and CD44v5 to be lower in
ovarian cancer patients than healthy control subjects, no statistical difference between the two cohorts was revealed for CD44 isoform v6. In
the ascitic fluid samples, variant isoform v5 and v6 were demonstrated at lower concentrations than serum. Multivariate analysis of overall
survival demonstrated that a high pretreatment serum level of soluble CD44 isoform v5 is independently associated with favourable clinical
outcome in ovarian cancer. When circulating CD44 isoforms were compared with a panel of serum parameters known to be involved in the
immunological network, an inverse correlation between serum CD44v5 levels and indicators of cellular immune system activation, such as
soluble interleukin 2 receptor, immunostimulatory protein 90K and neopterin, became apparent.
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The standard treatment of patients with advanced epithelial
ovarian cancer consists in surgical debulking followed by plat-
inum-containing chemotherapy. Despite the high initial objective
response rate ofovarian carcinomas to the various platinum-based
therapy regimens, the majority of patients ultimately develop
disease progression and die from complications of their cancer
within the first 5 years after diagnosis. Because of poor long-term
survival, more aggressive therapeutic strategies, including
intraperitoneal and high-dose chemotherapy with autologous bone
marrow rescue, are currently under discussion for introduction
into frontline chemotherapy.
However, criteria to be considered for the selection of patients
for these treatment regimens remain to be defined. A more accu-
rate assessment of prognosis is certainly of pivotal importance
when identifying patients who may benefit most from such
therapy protocols. In addition to the established clinicopatholog-
ical characteristics ofthe disease, new determinants offavourable
or aggressive tumour behaviour are needed to improve the estima-
tion ofindividual prognosis. Therefore, investigations focusing on
the evaluation ofnew prognostic factors are of significant interest.
In this regard, adhesion molecule CD44 has attracted attention
when certain of its variant isoforms conferred metastatic potential
on primarily non-metastasizing rat pancreatic tumour cell lines in
an animal tumour model (Gunthert et al, 1991; Seiter et al, 1993).
CD44 was first described by Jalkanen et al (1987) as alymphocyte-
homing receptor, regulating the entry of circulating lymphocytes
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into the lymphatic tissue by attachment to endothelial venules.
However, this adhesion molecule is not only present on lympho-
cytes but is ubiquitously expressed on cells of mesodermal and
haemopoietic origin (Terpe et al, 1994). CD44 acts as a principal
receptor for hyaluronate and is involved in cell-cell or cell-extra-
cellular matrix interactions (Miyake et al, 1990).
The CD44 gene consists of20 exons, ten ofwhich are constitu-
tively expressed in the standard form of CD44 (CD44s). By a
mechanism referred to as 'alternative messenger RNA splicing',
the remaining ten exons can be assembled in a variable number in
conjunction with CD44s transcripts, resulting in the synthesis ofa
variety of so-called CD44 variant isoforms (CD44v) that differ
from CD44s by additional amino acids inserted into the extracel-
lular domain of the protein. In a broad range of carcinomas,
including those of the stomach, colon, breast and ovary, overex-
pression ofspecific CD44 variant isoforms was shown to be asso-
ciated with poor prognosis (Heider et al, 1993; Mayer et al, 1993;
Mulder et al, 1994; Guinthert et al, 1995; Kaufmann et al, 1995;
Uhl-Steidl et al, 1995). Although the functions of CD44v in
tumour biology are not fully understood, it has been speculated
that certain alternatively spliced formns ofCD44 play a causal role
in tumour progression and particularly in lymphatic metastatic
spread (Salles et al, 1993; Seiter et al, 1993).
CD44 isoforms not only exist as membrane-integrated mole-
cules, but are also shed from the cellular surface and thus occur as
soluble CD44 molecules in body fluids. Monoclonal antibodies,
which have recently been raised against soluble CD44s and its
variant isoform-carrying domains encoded by exon v5 and v6,
enabled us to determine the pretreatment serum and ascitic levels
of these molecules in women suffering from ovarian cancer. The
major aim of the present investigation was the evaluation of the
prognostic value of CD44 variant isoforms in ovarian cancer. In
addition, we were interested in whether one or the other of these
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soluble CD44 molecules adequately reflects tumour burden.
Furthermore, serum and ascitic levels of these soluble proteins
were correlated to other established clinicopathological variables,
and in particular our interest focused on associations of soluble
CD44 proteins with a number of soluble serum parameters known
to be involved in the activated immunological network, such as
neopterin, soluble interleukin 2 receptor, immunostimulatory
protein 90K and immunosuppressive acidic protein (IAP).
MATERIALS AND METHODS
Patients
Patients (n = 96) aged 23-88 years (median 64 years), who under-
went primary surgery for epithelial ovarian cancer at the
Department of Obstetrics and Gynecology, Innsbruck University
Hospital, were included in this retrospective study. Surgical
debulking was followed by a platinum-containing chemotherapy.
The histopathological diagnoses were obtained from the
Gynecopathology Unit of our hospital. Patients were staged
according to the 1986 revised staging system of the International
Federation of Gynecology and Obstetrics (FIGO). Histological
subtype and FIGO stage distributions are listed in Table 1, together
with other important clinical characteristics. Excluded from the
study were subjects with conditions associated with expected acti-
vation or suppression ofthe immune system (i.e. acute inflamma-
tory disease, autoimmune disorders), as well as individuals with
secondary overt malignancies. None of the patients had a history
of previous systemic chemotherapy or radiation therapy. Survival
data from all the study patients were obtained from the database of
the gynecological oncology service. The control group consisted
of 50 healthy female blood donors giving informed consent for
Table 1 Clinical and histopathological characteristics of study patients
(n= 96)
Number of patients %
FIGO stage
26 27
11 6 6
III 55 58
IV 9 9
Ascites
None 42 44
<500ml 19 20
> 500 ml 35 36
Residual disease
None 44 46
<2cm 18 19
>2cm 34 35
Histological diagnosis
Serous cystadenocarcinoma 47 49
Mucinous cystadenocarcinoma 34 36
Endometrioid adenocarcinoma 4 4
Clear cell carcinoma 3 3
Undifferentiated carcinoma 8 8
Grade of differentiation
1 7 8
2 60 62
3 29 30
5 ml of serum to be subjected to scientific determination ofcircu-
lating CD44s and its variant isoforms.
Serum assays
Serum samples were taken before surgery and were stored at
-20°C until assayed. Serum concentrations of soluble CD44s,
CD44v5, and CD44v6 were measured using the commercially
available enzyme-linked immunosorbent assays: sCD44std
ELISA; sCD44var (v5) ELISA; and sCD44var (v6) ELISA. The
kits were a generous gift from Bender MedSystems (Bender,
Vienna, Austria). All determinations of soluble CD44 isoforms
were performed in triplicate according to the manufacturer's
instructions. The intra- and intra-assay coefficients of variation
(CV) were 5.3% and 3.2%, respectively, for the sCD44std assay,
6.2% and 4.8%, respectively, for the sCD44var (v5) assay and
5.8% and 5.0%, respectively, for the sCD44var (v6) assay. The
limits of detection determined by the manufacturer were
0.07 ng ml-', 0.22 ng ml-' and 0.09 ng ml-1 for the soluble CD44s,
CD44v5 and CD44v6 respectively.
Preoperative CA 125 serum levels were determined with a sand-
wich solid-phase radioimmunoassay (Centocor, Malvem, PA,
USA) according to the manufacturer's recommendations. The
inter-and intra-assay CV were 5.3% and 4.2% respectively.
Neopterin serum concentrations were measured using a radio-
immunoassay based on the double-antibody technique (Henning,
Berlin, Germany). Incubations were carried out under protection
from light according to the instructions ofthe manufacturer (inter-
and intra- assay CV 10.5% and 7.1% respectively).
The serum content of immunosuppressive acidic protein (IAP)
was measured with a single radial immunodiffusion test (Sanko
Junyaku, Tokyo, Japan). Five microlitres ofserum were applied to
each well ofthe gel plate containing anti-IAP rabbit serum. After
incubation at 37°C for60 h in a humid atmosphere the diameter of
the precipitation rings was measured. The values were compared
with those obtained from calibration standards of purified IAP
(inter-/intra-assay CV 5.7% and 3.7% respectively).
s-IL-2R was determined with an immunoenzymometric assay
kit purchased from Immunotech International (SA, Marseille,
France); inter- and intra-assay CV were 6.5% and 4.0% respec-
tively. Serum 90K was determined with a newly developed
immunoradiometric assay (IRMA), as described previously
(Zeimet et al, 1996). The inter- and intra-assay CV of this assay
were 7.2% and 4.4% respectively.
Haemoglobin concentration and total white blood cell count
were determined by the Clinical Chemistry Facility at Innsbruck
University Hospital; the normal range as defined by the 95%
confidence limit was 7.27-9.75 mmol 1-1 and 4-10 x 109 1-'
respectively.
Statistics
Statistical analysis was performed using the BMDP software
package. Data were analysed by non-parametric tests, and results
are expressed as median values with a first and third quartile.
Differences in median values were evaluated by the
Mann-Whitney U-test. Concentrations ofsoluble CD44s, CD44v5
and CD44v6 determined in serum and ascites of ovarian cancer
patients were analysed by means of a paired-Wilcoxon test.
Contingency tables were constructed and x2 statistics were calcu-
lated to analyse the frequencies of categorical parameters. The
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Figure 1 Serum levels of CD44s and its isoforms v5 and v6 as determined in 96 ovarian cancer patients (OVCA) and in 50 healthy control subjects. Overall
range, bars; interquartile [Q1-Q3] range, boxes; and median value, dark line
1- Table 2 Median concentrations of CD44s, CD44v5 and CD44v&with their
respective first and third quartiles [Q1; 03] as determined in the serum
(healthy control subjects, n = 50; ovarian cancer patients, n = 96) and the
ascitic fluid (ovarian cancer patients, n = 54). Comparisons between serum
concentrations in control subjects and ovarian cancer patients as well as
between serum and ascites concentrations are also indicated
CD44s (ng ml-1) CD44v5 (ng ml-') CD44v6 (ng ml-')
Healthy controls 382 29 131
(serum) [108;415] [21;40] [108;178]
Differences P< 0.001 P< 0.03 NS
Ovarian cancer 556 20.5 115
patients (serum) [424;658] [8.2;35] [75;142]
Differences NS P < 0.01 P < 0.001
Ovarian cancer 434 11 58
patients (ascites) [208;530] [4;15] [39;76]
survival ofovarian cancer patients was calculated from the time of
diagnosis by means ofthe product-limit method ofKaplan-Meier.
Differences in survival were examined according to Mantel and
Breslow. Cox proportional hazards analysis was used to identify
the independent prognostic factors. Relative risk (RR) was esti-
mated as the exponential function of the respective regression
coefficient. Correlations were estimated using the Spearman rank
correlation coefficient (rs). A P-value of < 0.05 was considered
significant.
RESULTS
Median serum concentrations of soluble CD44s and its variant
isoforms vS and v6 determined in the serum of 96 ovarian cancer
patients and in 50 healthy female blood donors are listed in Table 2
and shown in Figure 1, together with their corresponding first and
third quartiles [Q1; Q34. Whereas pretreatment CD44s serum
levels were significantly higher in ovarian cancer patients than in
healthy individuals (P < 0.001), serum CD44v5 concentrations
were found to be higher in healthy women than women suffering
from ovarian cancer (P < 0.03). Circulating CD44v6 levels were
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Figure 2 Survival of ovarian cancer patients stratified to pretreatment
CD44v5 serum levels greater than (dotted line) and less than/equal to (solid
line) 35 ng ml-'. Kaplan-Meier curves were found to be statistically different
(P < 0.01) when applying tests according to Mantel-Cox and Breslow
not significantly different in either group. In ovarian cancer, serum
CD44 variant isoform vS was correlated to circulating variant
isoform v6(rs 0.3993; P < 0.001), but neither ofthe soluble variant
isoforms was significantly related to CD44s.
Neither serum CD44s nor the investigated iioforms vS or v6
were found to be associated with standard clinicopathological vari-
ables, such as patient age, FIGO stage, histological tumour type,
tumour grade, haemoglobin concentration, total white blood cell
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Table 3 Patient characteristics stratified to the serum CD44v5
concentrations (cut-off point, 35 ng ml -1)
CD44v5 < 35 ng ml-' CD44v5 > 35 ng ml-1 Differences
(n= 72) (n= 24)
Age 66 60 NS
[54; 74] [48; 72]
FIGO
19 (26%) 7 (29%)
11 3 (4%) 3 (13%)
III 41 (57%) 14 (58%) NS
IV 9 (13%) 0 (0%)
Residual disease
0 34 (47%) 10 (44%)
< 2 cm 12 (17%) 6 (25%) NS
> 2 cm 26 (36%) 8 (32%)
Grade
1 5 (7%) 2 (7%)
2 41 (57%) 19 (81%) P<0.05
3 26 (36%) 3 (12%)
CA 125
637 U ml-' 342 U ml-1 P<0.03
[117; 1635] [79; 881]
Neopterin
57.5 ng ml-' 26 ng ml-' P< 0.03
[36; 75] [14; 35]
Protein 90K
6.7 U ml-' 4.3 U ml-' P < 0.05
[4.5; 11] [1.3; 5.9]
s-lL2-R
2.9 ng ml-' 1.8 ng ml-' NS
[1-9; 4.2] [1-1; 3.1]
IAP
810 g ml-' 755,ug ml-' NS
[607; 1067] [485; 992]
count, erythrocyte sedimentation rate, intraoperatively determined
volume of ascites and residual disease after primary debulking
surgery. It is worth noting, however, that serum concentrations of
variant isoform v5 tended to be inversely correlated to tumour
grade(r. = - 0.1979; P = 0.07).
When soluble CD44 isoforms were compared with other serum
parameters, variant isoform v5 was negatively related to immuno-
stimulatory protein 90K (rs = - 0.2152; P < 0.05), soluble inter-
leukin 2 receptor (s-IL-2R) (rs = - 0.2536; P < 0.05) and neopterin
(rs = -0.346; P < 0.01). In contrast, serum levels ofCD44 v6 were
negatively associated with serum CA-125 (rs = - 0.2585; P < 0.01)
and IAP(rs= - 0.2553; P < 0.01).
Fifty-four patients (56%) had significant amounts of ascites.
Concentrations ofsoluble CD44s, isoforms vS and v6 in the ascitic
fluid are shown in Table 2. Whereas vS and v6 content was signif-
icantly lowerin ascitic fluid than in serum (P < 0.01 and P < 0.001
respectively), CD44s did not differ in either compartment.
Analysis of overall survival revealed no prognostic value, either
for serum CD44s or for the v6 isoform. However, patients with
pretreatment concentrations ofcirculating variant isoform vS higher
than the Q3 value determined in the present collective (35 ng ml-')
showed a significantly better survival than patients presenting with
lower vS serum levels (P < 0.01) (Figure 2). During a median
follow-up period of29 months only 4 out of24 patients (17%) with
vS serum levels above the cut-offvalue of35 ng ml-' died from the
disease, whereas in the cohort ofpatients with lower circulating vS
concentrations 33 out of 72 patients (46%) died. Table 3 compares
characteristics ofpatients with circulating v5 isoform levels higher
than 35 ng ml-' with those ofpatients with lower vS serum content.
This comparison revealed that high-grade tumours are frequently
associated with vS serumlevels belowthecut-offvalue of35 ng ml-'
(P < 0.05) and that patients with low circulating CD44vS levels
showed significantly higher serum concentrations of CA-125,
neopterin (P<0.03) andimmunostimulatory protein 90K(P<0.05).
Furthermore, in multivariate Cox regression analysis (Table 4),
serum isoform vS retained independent prognostic significance
(RR 0.58; P < 0.05) together with FIGO stage (RR 4.5;
P < 0.0001), residual disease and histopathological grading (RR
1.89 and 2.4 respectively; P < 0.001). None of the various CD44
isoforms, when investigated in ascitic fluid, was found to be of
prognostic relevance.
Table 4 Multivariate Cox hazard analysis
Univariate Cox analysis Regression coefficient
Variable* P-value Value Standard error P-value Relative
risk
FIGO stage 0.0003 1.504 0.660 0.0001 4.5
Tumour grade 0.0035 0.875 0.3383 0.001 2.4
Residual disease 0.0049 0.642 0.2110 0.001 1.89
CD44s NS - - NS 1
CD44v5 0.007 -0.5447 0.0125 0.0341 0.58
CD44v6 NS - - NS 1
Neopterin 0.045 - - NS 1
Antigen 90K 0.048 - - NS 1
slL2-r 0.024 - - NS 1
IAP NS - - NS 1
CA-125 0.0012 - - NS 1
*Variables were used in dichotomized form: FIGO stages I and 11 vs iII and IV: tumour grade 1 vs 2 and 3; residual disease none vs macroscopically visible.
Serum parameters were also dichotomized according to their Q3 values.
British Journal ofCancer(1997) 76(12), 1646-1651 0 CancerResearch Campaign 19971650 AGZeimet etal
DISCUSSION
Soluble CD44s and its variant isoforms have been demonstrated in
the serum of cancer patients and healthy individuals. At present,
however, the exact in vivo function and the cellular source ofthese
soluble CD44 molecules remain uncertain. Guo et al (1994) first
reported increases in soluble CD44s serum levels in colon and
gastric cancer. As serum CD44s levels were closely related to
tumour burden, these authors proposed this molecule as a suitable
marker in patient monitoring.
In addition, the current investigation revealed higher circulating
CD44s levels in ovarian cancer patients than healthy control
subjects. CD44s serum content, however, was not related to FIGO
stage or tumour-associated antigen CA-125 and thus is not likely
to consistently reflect tumour load. Circulating CD44v6 did not
differ between ovarian cancer patients and healthy control
subjects, and soluble isoform vS was even significantly lower in
ovarian cancer patients. Recently, a decrease in serum CD44v5
levels was also reported in patients with prostate and renal cancer
(Lein et al, 1996). In agreement with the data ofSliutz et al (1995),
none of the herein investigated soluble isoforms of the CD44
family can be expected to represent a useful tumour marker in
ovarian cancer.
The association of high circulating levels of CD44v5 isoforms
with favourable prognosis represents a very interesting outcome of
the present study. Even although, to ourknowledge, the prognostic
significance ofsoluble CD44 isoforms has not yet been evaluated,
this finding was unexpected compared with the early experimental
data from studies obtained in a rat tumour model, in which cellular
expression of alternatively spliced CD44 variant isoforms
conferred metastatic potential or primarily non-metastasizing
pancreatic tumour cells (Gunthert et al, 1991; Arch et al, 1992).
Furthermore, a number of clinical studies have provided evidence
that up-regulation of certain CD44 isoforms in tumour cells is
related to adverse clinical outcome (Mayer et al, 1993; Gunthert et
al, 1995; Stauder et al, 1995). However, the results concerning the
prognostic value of the immunohistochemically assessed cellular
expression of CD44 variant isoforms have been controversial in
breast, colorectal and ovarian cancer (Mulder et al, 1994;
Cannistra et al, 1995; Friedrichs et al, 1995; Kaufmann et al, 1995;
Koretz et al, 1995; Uhl-Steidl et al, 1995).
In 44 patients with advanced ovarian cancer, tissue expression
of CD44 splice variants, detected immunohistochemically by
polyclonal antibody-recognizing variant exons v3-vlO of human
CD44, was found to be associated with short disease-free and
overall survival in univariate analysis (Uhl-Steidl et al, 1995). In
an additional study, however, tissue expression of CD44s and its
various alternatively spliced isoforms, as determined by mono-
clonal antibodies and reverse transcription polymerase chain reac-
tion, failed to exhibit an association with survival in 31 ovarian
cancer patients (Cannistra et al, 1995). These authors commonly
detected CD44s and isoform v9, but not the isoforms vS or v6, in
ovarian cancer tissue (Cannistra et al, 1995). Accordingly, Sliutz et
al (1995) demonstrated only traces ofCD44v5 and v6 proteins in 2
out of 22 immunohistochemically investigated ovarian carcinoma
samples. This is in agreement with our own observations based on
immunohistochemical studies using the monoclonal antibodies
VFF-8 and VFF-7, which recognize CD44 variant isoforms vS and
v6 respectively (data not shown).
Modest immnunohistochemical detection alone does not neces-
sarily exclude ovarian cancer cells as a source of soluble CD44
variant isoforms, as Yu and Toole (1996) recently demonstrated
mRNA for CD44 isoforms that contained stop codons positioned so
that translated proteins are truncated before the transmembrane
domain andthus secreteddirectly as soluble molecules without tran-
sient membrane integration. However, the unconvincing immuno-
histochemical results in the detection of isoforms vS and v6 in
ovarian cancer tissue together with the findings ofthe current inves-
tigation, showing that CD44v5 serum content is lower in ovarian
cancer patients than in healthy female control subjects and that
splice variants v5 and v6 are present at significantly lower levels in
ascitic fluid than in serum, indicate that ovarian cancer cells are not
arelevant source ofcirculating CD44 isoforms v5 and v6.
As the present study reveals that soluble CD44v5 was inversely
correlated with circulating immunostimulatory protein 90K, s-IL-2-
R and serum neopterin, all ofwhich belong to a group ofmolecules
regarded as indicators ofcellular immune-system activation (Marth
et al, 1993; 1994; Zeimet et al, 1996), it cannot be ruled out that
changes in systemic levels of soluble CD44v5 are due to tumour-
induced alterations in the host's immune defence. This hypothesis
is conceivable as expression of CD44 isoforms, including that of
v5, in peripheral blood leucocytes was recently found to be
inversely correlated to tumour progression in patients with haema-
tological malignancies (Khaldoyanidi et al, 1996). The assumption
ofimmunologically induced changes in systemic CD44v5 levels is
further supported by the postulated pivotal role of cytokines in
shedding soluble CD44 isoforms (Ristamaki et al, 1994).
To elucidate the involvement ofthe immune system in the regu-
lation of circulating CD44 variant isoforms, we are currently
investigating the constitutive and cytokine-modulated secretion of
CD44 isoforms by immunocompetent cells under in vitro condi-
tions. In addition, a prospective evaluation in a larger cohort is
required to substantiate further the association of high circulating
CD44v5 levels with favourable clinical course in ovarian cancer
patients.
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